Journal of Chromatography & Separation Techniques
Open Access
ISSN: 2157-7064
+44 1300 500008
ISSN: 2157-7064
+44 1300 500008
Wei-Hsi Chen
Institute of Nuclear Energy Research, Taiwan (ROC)
Posters & Accepted Abstracts: J Chromatogr Sep Tech
The radio-isotope Re-188-labeled ligand with amino-amido-dithiol (N2S2) tetradentate and hexadecyl carboxylate ethyl ester (Re- 188-MN16ET) dissolved in lipiodol has been served as radio-transcatheter arterial embolization (TAE) therapeutic medicine under preclinical study for hepatocellular carcinoma (HCC). The impurities of its precursor, trimethylphenyl protected- H3MN16ET arose from the preparative processes and metabolites of Re-MN16ET in hepatic medium were identified by HPLC coupled with electrospray ionization tandem mass spectrometry (HPLC-tandem MS) based on m/z of protonated molecular ions and multi-fragmentation ions obtained from triple quadrupole-linear ion trap (QqQ-LIT) and quadrupole-time of flight (Q-ToF) mass spectrometry. The molecular structure of unknowns (including impurities in protected-H3MN16ET and metabolites from bio-transformation of Re- MN16ET) were directed by sketching fragmentation profiles. There were 2 impurities identified in protected-H3MN16ET and 2 metabolites (Re-MN16-CO2H and de-ReO-MN16-CO2H with disulfide bond) involved in hepatic biotransformation of Re-MN16ET. The potential deteriorate pathways of protected-H3MN16ET were also found. The methodology was advanced applied to solve the identity of derivatives which come from Re-188 labeling process for protected-H3MN16ET into end-product, Re-188-MN16ET.
Email: whchen@iner.gov.tw